ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd

MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevance is unknown but could it result in a novel Rx pathway? ? Effect of sex & smoking @RheumNow @eular_org abst OP0007 #EULAR2021 https://t.co/8XpKjPFfUX

To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb

Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm

Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs